Evidence map›Paper›PMID 27496023›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery.

J Arredondo, J Baixauli, C Pastor, A Chopitea, J J Sola, I González, J A-Cienfuegos, P Martínez, J Rodriguez, J L Hernández-Lizoain

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 4 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. The ELECLA trial: A multicentre randomised control trial on outcomes of neoadjuvant treatment on locally advanced colon cancer.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

J ArredondoDepartment of General Surgery, Complejo Asistencial Universitario de León, c/Altos de Nava s/n, 24008, León, Spain. jarredondo@outlook.es.ORCID http://orcid.org/0000-0001-8077-6092
J BaixauliDepartment of General Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
C PastorDepartment of General Surgery, Fundación Jiménez-Díaz, Madrid, Spain.
A ChopiteaDepartment of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
J J SolaDepartment of Pathology, Hospital San Pedro, Logroño, Spain.
I GonzálezDepartment of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.
J A-CienfuegosDepartment of General Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
P MartínezDepartment of General Surgery, Centro Médico de Asturias, Oviedo, Spain.
J RodriguezDepartment of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
J L Hernández-LizoainDepartment of General Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
Clinica Universidad de Navarra · ESHospital de León · ESHospital San Pedro · ESHospital Universitario Fundación Jiménez Díaz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNeoadjuvant chemotherapy is being actively tested as an emerging alternative for the treatment of locally advanced colon cancer (LACC) patients, resembling its use in other gastrointestinal tumors. This study assesses the mid-term oncologic outcome of LACC patients treated with oxaliplatin and fluoropyrimidines-based preoperative chemotherapy followed by surgery. METHODS AND PATIENTS: Patients with radiologically resectable LACC treated with neoadjuvant therapy between 2009 and 2014 were retrospectively analyzed. Radiological, metabolic, and pathological tumor response was assessed. Both postoperative complications, relapse-free survival (RFS), and overall survival (OS) were studied.

resultsSixty-five LACC patients who received treatment were included. Planned treatment was completed by 93.8 % of patients. All patients underwent surgery without delay. The median time between the start of chemotherapy and surgery was 71 days (65-82). No progressive disease was observed during preoperative treatment. A statistically significant tumor volume reduction of 62.5 % was achieved by CT scan (39.8-79.8) (p < 0.001). It was also observed a median reduction of 40.5 % (24.2-63.7 %) (p < 0.005) of SUV

conclusionPreoperative chemotherapy in LACC patients is safe and able to induce major tumor regression. Survival times are encouraging, and further research seems warranted.

Indexed as

Neoadjuvant TherapyAdenocarcinomaAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineColonic NeoplasmsCombined Modality TherapyFemaleFluorouracilFollow-Up StudiesHumansMaleNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingOrganoplatinum CompoundsCapecitabineFluorouracilOrganoplatinum CompoundsOxaliplatinFluoropyrimidinesOxaliplatinPreoperative chemotherapySurvivalTumor response

Identifiers

PMID27496023
OpenAlexW2481469487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.